I write about medical AI and the claims people make about building muscle. I read the studies, figure out what holds up, and explain where I still have questions.
Read the latest →I follow what happens when an algorithm leaves the research paper and ends up beside a doctor, a scan, or a hospital bed.
AI & MedicineI sort useful training evidence from supplement marketing, especially when a claim sounds much cleaner than the biology is.
Anabolics
I read the clinical trials behind medical AI. Some systems helped the workflow. Others did their assigned job without improving patient care.
In a live hospital workflow, LiON helped reviewers find 15 malignancies that had been overlooked on liver scans.
The FDA's draft idea would test a medical AI before release, confirm it in a clinic, and keep checking it after updates.
Beta-alanine builds muscle carnosine over time. It helps most when a hard effort lasts roughly one to four minutes.
A sepsis alert is useful only when someone responds. The strongest hospital studies show why.
Testosterone can add muscle. Using it without a medical need also suppresses natural production and creates risks gym advice tends to skip.
A 71-person phase 2a trial moved rentosertib beyond an AI discovery claim. The lung-function result still needs a larger test.
An AI risk score has value when it leads to a concrete change, such as treating LDL or ordering the right follow-up scan.
Researchers tested 44 products sold online as SARMs. Only about half actually contained a SARM.
The MASAI trial included more than 80,000 women. AI support cut reading workload while finding at least as many cancers.
In a 31,301-woman trial, AI cleared low-risk mammograms and cut reading workload by 63.6%. It also increased recalls.
The 30-minute anabolic window is mostly gym mythology. Total daily protein comes first; meal timing is a smaller detail.
A chatbot can make a medical answer sound clear even when it missed the one detail that changes the advice.
AI already flags scans and drafts reports. Radiologists still have to handle the strange cases and own the final call.
Caffeine helps performance at surprisingly ordinary doses. Taking more mostly raises the chance that sleep pays for it later.
One week of five-hour nights lowered daytime testosterone in a small study of healthy young men. One late night does not establish the pattern.
Fast weight loss can include lean mass. Resistance training and enough protein should be part of the plan from day one.
BPC-157 has a huge online reputation and almost no convincing human evidence for healing an injury.
Creatine and caffeine have evidence. Most of the supplement aisle has marketing copy and a much thinner research file.
A large meta-analysis found the added benefit leveling off around 1.6 grams of protein per kilogram per day.
In healthy adults, HGH can raise measured lean mass without producing the strength gains its reputation suggests.
A triage score can catch a patient who looks stable and is getting worse. Hospitals still need to show who acts on the warning.
Creatine monohydrate is cheap, heavily studied, and useful for repeated hard efforts. Three to five grams a day is enough for most people.
An ambient scribe drafts the visit note while the doctor talks with the patient. The useful outcome may be more eye contact.
Carbohydrate needs change with the work. A long practice burns through more glycogen than a short lifting session.
A small calorie surplus gives training room to work. Eating far past it mostly makes the later cut longer.
The workout creates fatigue. Sleep is when the body gets a chance to adapt before the next one.
A surgical robot follows the surgeon's hands. Whether it helps depends on the operation and the experience of the person at the console.
AlphaFold made protein structures easier to predict. A useful drug still has to pass chemistry and years of human testing.
Continuous glucose monitors already guide treatment. Many other wearable signals still create more data than clear medical decisions.
AI can give doctors time back and still make a dangerously convincing mistake. The job we give it determines how useful it is.
In the Casgevy trial, 29 of 31 evaluable patients avoided severe sickle-cell pain crises for at least a year.
AI can mark a suspicious patch on a digital slide. A pathologist still decides what those cells mean for the patient.
Connected implants can report a rhythm change or device problem from home. Someone still has to watch the alert.
Photon-counting CT, shorter MRI scans, and portable machines are changing who can get a useful image and how long it takes.
Speech may contain clues about depression. Using those clues without consent would turn a screening idea into surveillance.
I'm Jack Nassiri, a Loyola High School student and writer for The Loyalist. This is where I work through the health research I cannot stop reading about.